Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin
Top Cited Papers
- 30 September 2005
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Hepatology
- Vol. 43 (3), 425-433
- https://doi.org/10.1016/j.jhep.2005.04.009
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirinJournal of Hepatology, 2005
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studiesJournal of Antimicrobial Chemotherapy, 2003
- Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis CHepatology, 2003
- Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CHepatology, 2003
- Viral and immunological determinants of hepatitis C virus clearance, persistence, and diseaseProceedings of the National Academy of Sciences of the United States of America, 2002
- National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002Hepatology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionThe New England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001